Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Georges, Weissgerber"'
Autor:
Stephen H. Poor, Georges Weissgerber, Christopher M. Adams, Harit Bhatt, David J. Browning, James Chastain, Thomas A. Ciulla, Michael Ferriere, Kinfemichael Gedif, Louis C. Glazer, Brian C. Joondeph, Guillaume Normand, Veeral Sheth, Christie Watters, Cynthia L. Grosskreutz
Publikováno v:
American Journal of Ophthalmology. 239:180-189
To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti-vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age
Autor:
Ursula Schmidt-Erfurth, Zufar Mulyukov, Bianca S. Gerendas, Gregor S. Reiter, Daniel Lorand, Georges Weissgerber, Hrvoje Bogunović
Publikováno v:
Eye. 37:1160-1169
Objectives To assess the therapeutic response to brolucizumab and aflibercept by deep learning/OCT-based analysis of macular fluid volumes in neovascular age-related macular degeneration. Methods In this post-hoc analysis of two phase III, randomised
Publikováno v:
Clinical Ophthalmology.
Lee Shettle,1 Eugene McLaurin,2 Joseph Martel,3 John W Seaman III,4 Georges Weissgerber5 1Shettle Eye Research, Inc, Largo, FL, USA; 2Total Eye Care, Memphis, TN, USA; 3Research Center, Martel Eye Medical Group, Rancho Cordova, CA, USA; 4Novartis Pha
Autor:
Ursula Schmidt-Erfurth, Rishi P Singh, Georges Weissgerber, Adrian Koh, Frank G. Holz, Pravin U. Dugel, Kinfemichael Gedif, Yuichiro Ogura, Glenn J. Jaffe, Ramin Tadayoni
Publikováno v:
Ophthalmology. 128:89-99
Purpose To report the 96-week outcomes from HAWK and HARRIER. Design Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of brolucizumab 3 mg (HAWK only) and 6 mg with aflibercept 2 mg in eyes with neova
Autor:
Pravin U. Dugel, Chirag D. Jhaveri, Usha Chakravarthy, Charles C. Wykoff, Rishi P. Singh, Robin Hamilton, Georges Weissgerber, Zufar Mulyukov, Frank G. Holz
Publikováno v:
Dugel, P U, Jhaveri, C D, Chakravarthy, U, Wykoff, C C, Singh, R P, Hamilton, R, Weissgerber, G, Mulyukov, Z & Holz, F G 2022, ' Effect of retinal thickness variability on visual outcomes and fluid persistence in neovascular age-related macular degeneration: a post hoc analysis of the HAWK and HARRIER studies ', Retina (Philadelphia, Pa.), vol. 42, no. 3, pp. 511-518 . https://doi.org/10.1097/IAE.0000000000003349
To determine the association between central subfield thickness (CST) variability and visual outcomes in eyes with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapies.In this post hoc, treatment
Autor:
Theodore A, Pasquali, Melissa M, Toyos, David B, Abrams, David K, Scales, John W, Seaman, Georges, Weissgerber
Publikováno v:
Translational Vision Science & Technology. 11:14
Licaminlimab is a new anti-TNFα antibody fragment for topical ocular application. This phase II study assessed the tolerability, treatment effect, and pharmacokinetics of licaminlimab in acute anterior uveitis (AAU).In this multicenter, randomized,
Autor:
Tomohiro Iida, Jordi Monés, Yuichiro Ogura, Divya D'Souza, Glenn J. Jaffe, Chui Ming Gemmy Cheung, Adrian Koh, Andrew Chang, Won Ki Lee, Gregg T. Kokame, Georges Weissgerber, Kanji Takahashi, Kinfemichael Gedif
Publikováno v:
The British journal of ophthalmology. 106(7)
PurposeTo compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study.DesignHAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial
Autor:
Ulrich F O Luhmann, José Cunha-Vaz, Steffen Schmitz-Valckenberg, Hannah Dunbar, Matthias Schmid, Rufino Silva, Frank G Holz, Sergio Leal, Georges Weissgerber, Jan Henrik Terheyden, Charlotte Behning, David P. Crabb, Robert P. Finger, Adnan Tufail
Publikováno v:
Ophthalmologica
The slow progression of early age-related macular degeneration (AMD) stages to advanced AMD requires the use of surrogate end points in clinical trials. The use of combined end points may allow for shorter and smaller trials due to increased precisio
Autor:
Ramin Tadayoni, Andreas Clemens, Rohini Kumar Verma, Laura Sararols, Frank G. Holz, Georges Weissgerber
Publikováno v:
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 244(2)
Background: Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD). Purpose
Autor:
Pravin U, Dugel, Rishi P, Singh, Adrian, Koh, Yuichiro, Ogura, Georges, Weissgerber, Kinfemichael, Gedif, Glenn J, Jaffe, Ramin, Tadayoni, Ursula, Schmidt-Erfurth, Frank G, Holz
Publikováno v:
Ophthalmology. 128(1)
To report the 96-week outcomes from HAWK and HARRIER.Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of brolucizumab 3 mg (HAWK only) and 6 mg with aflibercept 2 mg in eyes with neovascular age-relat